La Renon Healthcare Pvt. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
La Renon Healthcare Pvt. Ltd. - overview
Established
2007
Location
Ahmedabad, IN-GJ-Gujarat, India
Primary Industry
Pharmaceuticals
About
Based in Gujarat, India, and founded by Pankaj Singh (Chairman and MD) in 2007, La Renon Healthcare Pvt. Ltd. operates as a developer and manufacturer of pharmaceutical products. In September 2025, a consortium led by White Oak Capital Management, Siguler Guff, Creador and Avendus PE Investment Advisors acquired approximately 10% minority stake in La Renon Healthcare Pvt.
Ltd for INR 110 billion. The company offers pharmaceutical products and services for various critical illnesses and diseases such as Nephrology, Critical Care, CNS, Gastroenterology, Urology, Cardio-Metabolic, Respiratory, and Gynaecology. Some examples of La Renon's products include Silodosin 8 mg Tablets for Benign Prostatic Hyperplasia, Amisulpride Injection 5mg/2ml for post-operative nausea and vomiting therapy, Alfuzosin 10mg Prolonged Release Tablets for Urology, etc. La Renon also has an in-house research and development (R&D) center, developing formulations and processes, transferring technology to manufacturing facilities like Stanford Labs, a subsidiary.
La Renon Healthcare Pvt. Ltd. generates revenue by manufacturing and selling branded chronic‑therapy pharmaceutical formulations across nephrology, CNS, gastro, gynaecology and cardio‑diabetology segments, supported by nationwide distribution. The September 2025 enables the company to accelerate growth across chronic therapy segments by strengthening its capital base and attracting global institutional investors.
The partnership with Creador, along with White Oak and Siguler Guff, provides strategic expertise and resources to expand product portfolios, scale operations, and enhance market presence both domestically and internationally.
Current Investors
A91 Partners, ChrysCapital, Sequoia
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.larenon.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
La Renon Healthcare Pvt. Ltd. - financials
| Fiscal Year Ended | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 715,405,861 | 1,198,180,681 | 1,993,670,479 | 2,845,441,854 | 3,529,299,979 | 4,797,618,017 | 5,888,225,454 | 6,902,772,953 | 5,586,412,000 | 8,352,766,000 | - | - | - |
| % Revenue Growth (YoY) | - | 67.5% | 66.4% | 42.7% | 24.0% | 35.9% | 22.7% | 17.2% | (19.1%) | 49.5% | - | - | - |
| EBITDA (USD) | 106,500,900 | 142,842,708 | 253,783,656 | 525,678,308 | 450,793,817 | 741,629,622 | 879,239,106 | 1,499,816,457 | 1,494,187,000 | 1,738,599,000 | - | - | - |
| Operating Income (USD) | 98,684,031 | 130,451,876 | 227,757,024 | 486,128,554 | 397,285,380 | 697,134,054 | 819,551,835 | 1,430,553,304 | 1,356,732,000 | 1,528,028,000 | - | - | - |
| Operating Margin | 13.8% | 10.9% | 11.4% | 17.1% | 11.3% | 14.5% | 13.9% | 20.7% | 24.3% | 18.3% | - | - | - |
| % EBITDA Margin | 14.9% | 11.9% | 12.7% | 18.5% | 12.8% | 15.5% | 14.9% | 21.7% | 26.7% | 20.8% | - | - | - |
| NET Income (USD) | 62,210,631 | 80,308,185 | 134,682,830 | 294,647,194 | 253,391,341 | 464,175,728 | 548,401,832 | 1,075,009,420 | 1,034,111,000 | 1,183,741,000 | - | - | - |
| % Net Margin | 8.7% | 6.7% | 6.8% | 10.4% | 7.2% | 9.7% | 9.3% | 15.6% | 18.5% | 14.2% | - | - | - |
La Renon Healthcare Pvt. Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | La Renon Healthcare Pvt. Ltd. | - | ||||||||
| Secondary Buyout | Completed | La Renon Healthcare Pvt. Ltd. | - | ||||||||
| Unspecified Round | Completed | La Renon Healthcare Pvt. Ltd. | - | ||||||||
| Add-on | Completed | Enaltec Labs Private Limited | - | ||||||||
| Unspecified Round | Completed | La Renon Healthcare Pvt. Ltd. | - |
Displaying 1 - 5 of 6
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.